Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bast

Showing results (321-330 of 560) with videos related to

Pageof 56
Sort By:
Cancer|October 25, 1991
Coordinate elevation of serum markers in ovarian cancer but not in benign diseaseR C Bast, S Knauf, A Epenetos, et al.
Gynecologic Oncology|September 1, 1985
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinomaR C Bast, F P Siegal, C Runowicz, et al.
Hybridoma|October 28, 1998
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissuesR C Bast, L Pusztai, B J Kerns, et al.
Molecular Cancer Research : MCR|May 23, 2024
Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing AutophagyJanice M Santiago-O'Farrill, Alicia Blessing Bollu, Hailing Yang, et al.
Seminars in Oncology|November 13, 2003
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancerGordon B Mills, Elise Kohn, Yiling Lu, et al.
Chronobiologia|July 11, 1992
Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacyG Cornélissen, F Halberg, E Halberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cellsG S Dean, L Pusztai, F J Xu, et al.
International Journal of Cancer|January 15, 1989
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cellsC M Boyer, M J Borowitz, K S McCarty, et al.
Gynecologic Oncology|February 1, 1990
CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancerV J Hunter, J B Weinberg, A F Haney, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 17, 2015
Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivoYanyan Ma, Zengtao Wei, Robert C Bast, et al.
Pageof 56

Showing results (321-330 of 560) with videos related to

Sort By:
Pageof 56
Cancer|October 25, 1991
Coordinate elevation of serum markers in ovarian cancer but not in benign diseaseR C Bast, S Knauf, A Epenetos, et al.
Gynecologic Oncology|September 1, 1985
Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinomaR C Bast, F P Siegal, C Runowicz, et al.
Hybridoma|October 28, 1998
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissuesR C Bast, L Pusztai, B J Kerns, et al.
Molecular Cancer Research : MCR|May 23, 2024
Crizotinib Enhances PARP Inhibitor Efficacy in Ovarian Cancer Cells and Xenograft Models by Inducing AutophagyJanice M Santiago-O'Farrill, Alicia Blessing Bollu, Hailing Yang, et al.
Seminars in Oncology|November 13, 2003
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancerGordon B Mills, Elise Kohn, Yiling Lu, et al.
Chronobiologia|July 11, 1992
Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacyG Cornélissen, F Halberg, E Halberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 1998
Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cellsG S Dean, L Pusztai, F J Xu, et al.
International Journal of Cancer|January 15, 1989
Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cellsC M Boyer, M J Borowitz, K S McCarty, et al.
Gynecologic Oncology|February 1, 1990
CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancerV J Hunter, J B Weinberg, A F Haney, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 17, 2015
Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivoYanyan Ma, Zengtao Wei, Robert C Bast, et al.
Pageof 56